Mitsubishi UFJ Financial Group Initiates Coverage on Charles River Laboratories (CRL)

James Marshall
April 20, 2018

According to Zacks, analysts expect that Charles River Laboratories Intl. will report full year earnings of $5.06 per share for the current year, with EPS estimates ranging from $5.00 to $5.10. It has outperformed by 9.73% the S&P500.

Spark Investment Management Llc decreased Charles Riv Labs Intl Inc (CRL) stake by 42.43% reported in 2017Q4 SEC filing. The company's stock sank 1.14% while Healthinvest Partners Ab sold 34,100 shares. Following the transaction, the director now directly owns 36,461 shares of the company's stock, valued at $3,963,310.70. Out of 2 Wall Street analysts rating Celadon Group, 1 give it "Buy", 0 "Sell" rating, while 1 recommend "Hold". About 228,769 shares traded. AT&T Inc. (NYSE:T) has declined 15.88% since April 19, 2017 and is downtrending. It has underperformed by 27.43% the S&P500. Smithfield Trust holds 0% of its capital in Charles River Laboratories International, Inc. The company has market cap of $95.64 million. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. It has a 40.12 P/E ratio.

Investors sentiment decreased to 1.08 in Q4 2017. The company has a market cap of $5,062.56, a price-to-earnings ratio of 19.84, a PEG ratio of 1.49 and a beta of 0.68. 39 funds took positions and 104 increased positions. (NYSE:CRL). D E Shaw has invested 0.06% of its portfolio in Charles River Laboratories International, Inc. (NYSE:CRL) earned "Hold" rating by KeyBanc Capital Markets on Thursday, October 12. Liberty Mutual Group Asset Mngmt has invested 0.01% in Leucadia National Corporation (NYSE:LUK). The medical research company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.26 by $0.14. Cardinal Capital Mgmt reported 8,335 shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 2,568 shares. Ngam Lp holds 0.02% or 16,196 shares. (NASDAQ:INGN). The Illinois-based Driehaus Mgmt Ltd Llc has invested 0.65% in Inogen, Inc.

Today, Mitsubishi UFJ Financial Group initiated coverage on NYSE:CRL - Charles River Laboratories (NYSE:CRL) with a Neutral with a price target of $115.00. Charles Riv Labs Intl Inc now has $5.18B valuation. Winfield holds 35 shares. Following the transaction, the insider now directly owns 21,276 shares in the company, valued at $2,299,510.08.

Since January 2, 2018, it had 0 buys, and 21 selling transactions for $10.85 million activity. Also, insider Birgit Girshick sold 9,893 shares of the firm's stock in a transaction on Tuesday, March 6th. Charles River Laboratories posted earnings of $1.29 per share in the same quarter last year, which would indicate a negative year over year growth rate of 3.1%. (NYSE:CRL). Shine Invest Advisory reported 343 shares. Amalgamated Bank now owns 9,905 shares of the medical research company's stock worth $1,084,000 after buying an additional 514 shares during the last quarter. (NYSE:CRL) was sold by CHUBB STEPHEN D. The insider Barbo William D sold $250,741. (NYSE:CRL). 3,676 are owned by Hsbc Holdings Public Limited Company. Over the last ninety days, insiders have sold 62,658 shares of company stock worth $6,875,393. SunTrust Banks downgraded Charles River Laboratories from a buy rating to a hold rating and lifted their price objective for the stock from $107.89 to $111.00 in a research report on Monday, January 22nd. Therefore 39% are positive. Charles River Laboratories had 46 analyst reports since August 3, 2015 according to SRatingsIntel. Robert W. Baird maintained Charles River Laboratories International, Inc. The company now has an average rating of "Buy" and an average price target of $116.71. Oppenheimer maintained the stock with "Hold" rating in Tuesday, July 25 report. (NYSE:CRL) on Tuesday, February 13 with "Hold" rating. On Wednesday, March 14 the stock of Charles River Laboratories International, Inc. (NYSE:CRL) on Thursday, November 2 with "Hold" rating. Morgan Stanley reissued an "equal weight" rating and issued a $102.00 price target (up from $94.00) on shares of Charles River Laboratories in a report on Wednesday, March 14th. The stock rating was maintained by Jefferies with "Buy" on Monday, November 13. The stock has "Mkt Outperform" rating by Avondale on Wednesday, August 31. On Monday, November 13 the stock rating was maintained by Robert W. Baird with "Buy".

Investors sentiment increased to 1.15 in 2017 Q4. Its down 0.05, from 0.71 in 2017Q3. Legal & General Group Plc raised its stake in Charles River Laboratories by 15.8% during the 3rd quarter. (NYSEAMERICAN:BTX). 5.30 million were reported by Blackrock Inc. (NYSE:CRL) shares. $312,172 worth of Charles River Laboratories International, Inc. Sageworth reported 20 shares. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company's stock valued at $145,000 after buying an additional 548 shares during the period. Guggenheim Capital Lc stated it has 119,014 shares or 0.03% of all its holdings. Cabot Corp. (NYSE:CBT) was reduced too. The Asset-Based segment offers dry van, refrigerated, and flatbed services; cross-border services between the United States and each of Mexico and Canada; intra-Mexico and intra-Canada services; contract services; regional and specialized short haul services; and rail intermodal services. Pembroke Management Ltd stated it has 77,535 shs. Kennedy Capital Management has 79,072 shares. (NYSEAMERICAN:BTX) or 29.97 million shares. (NYSE:T) or 74,627 shares. The SI to IMPALA PLATINUM HOLDINGS LTD ORDINARY SH's float is 0.39%. (NYSE:UAL) or 20,000 shares. (NYSE:UAL) for 22,145 shares. Adage Prns Limited Liability Com holds 0.04% or 150,000 shs in its capital. Eight equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock.

CRL has been the topic of several analyst reports. If the $152.50 price target is reached, the company will be worth $211.61 million more. Needham maintained Inogen, Inc. (NYSE:UAL) on Wednesday, January 24 with "Hold" rating.

Other reports by Click Lancashire

Discuss This Article